US3764703A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Amino acid mixture for use in treatment of uremic conditions
Assignee: AstraZeneca AB
•
Filing: 1970-11-03
•
Granted: 1973-10-09
•
Expires: 1990-11-03
Abstract
Abstract A mixture intended for nitrogen nutrition is disclosed which contains as a source of nitrogen a mixture of essential amino acids optionally combined with certain semi-essential amino acids. The mixture may be administered in either tablet or solution form to the patient and causes a lowering in blood urea nitrogen in combination with a positive nitrogen accumulation.
Inventors
- 👤 L Bergstrom
- 👤 N Bucht
- 👤 E Hultman
- 👤 D Dahlinder
- 👤 P Furst
- 👤 B Josephson
- 👤 E Vinnars
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 06:15
CPC Classifications
A; A23; A23L; A23L33/00; A23L33/10; A23L33/17; A23L33/175
Claims Analysis
Total Claims: 33
Claim 1
Independent Claim
18 words
A mixture as claimed in claim 1 which further comprises L-histidine in the proportion of about 0.0070-0.0450 moles.
Claim 2
Dependent Claim
18 words
A mixture as claimed in claim 2 which further comprises L-arginine in the proportion of about 0.0125-0.0800 moles.
Claim 3
Dependent Claim
48 words
A mixture as claimed in claim 1 which comprises amino acids in the following proportions: 0.0375-0.0675 moles of L-phenyl alanine 0.0500-0.0850 moles of L-leucine 0.0425-0.0750 moles of L-methionine 0.0075-0.0125 moles of L-tryptophan 0.0300-0.0550 moles of L-isoleucine 0.0325-0.0575 moles of L-lysine 0.0225-0.0425 moles of L-threonine 0.0400-0.0700 moles of L-valine.
Claim 4
Dependent Claim
14 words
A mixture as claimed in claim 4 which further comprises 0.0200-0.0375 moles of L-histidine.
Claim 5
Dependent Claim
14 words
A mixture as claimed in claim 5 which further comprises 0.0375-0.0650 moles of L-arginine.
Claim 6
Dependent Claim
76 words
An infusion solution intended for intravenous nutrition comprising: 0.0130-0.0850 moles of L-phenyl alanine 0.0165-0.1050 moles of L-leucine 0.0145-0.0900 moles of L-methionine 0.0025-0.0200 moles of L-tryptophan 0.0105-0.0700 moles of L-isoleucine 0.0110-0.0700 moles of L-lysine 0.0080-0.0550 moles of L-threonine 0.0135-0.0850 moles of L-valine per liter of solution in water, the pH of which solution being adjusted to fall within the interval 6.0 to 7.0 by addition of a pharmaceutically acceptable organic acid containing only carbon, oxygen and hydrogen.
Claim 7
Dependent Claim
23 words
An infusion solution according to claim 7, wherein the solution also contains 0.0125-0.0800 moles of L-arginine and 0.0070-0.0450 moles of L-histidine per liter.
Claim 8
Dependent Claim
18 words
An infusion solution according to claim 7, wherein the solution also contains 0.0070-0.0450 moles of L-histidine per liter.
Claim 9
Dependent Claim
45 words
An infusion solution according to claim 7, comprising: 0.0375-0.0675 moles of L-phenyl alanine 0.0500-0.0850 moles of L-leucine 0.0425-0.0759 moles of L-methionine 0.0075-0.0125 moles of L-tryptophan 0.0300-0.0550 moles of L-isoleucine 0.0325-0.0575 moles of L-lysine 0.0225-0.0425 moles of L-threonine 0.0400-0.0700 moles of L-valine per liter of solution.
Claim 10
Dependent Claim
23 words
An infusion solution according to claim 10, wherein the solution also contains 0.0375-0.0650 moles of L-arginine and 0.0200-0.0375 moles of L-histidine per liter.
Claim 11
Dependent Claim
18 words
An infusion solution according to claim 10, wherein the solution also contains 0.0200-0.0375 moles of L-histidine per liter.
Claim 12
Dependent Claim
31 words
An infusion solution according to claim 7, wherein the pH of the solution is adjusted to fall within the interval 6.0 to 7.0 by addition of a pharmaceutically acceptable organic acid.
Claim 13
Dependent Claim
28 words
An infusion solution according to claim 7, wherein the pH of the solution is adjusted to fall within the interval 6.0 to 7.0 by addition of acetic acid.
Claim 14
Dependent Claim
90 words
Method for the treatment of uremic conditions caused by renal insufficiency comprising administering by intravenous infusion to a patient a solution of: 0.0130-0.0850 moles of L-phenyl alanine 0.0165-0.1050 moles of L-leucine 0.0145-0.0900 moles of L-methionine 0.0025-0.0200 moles of L-tryptophan 0.0105-0.0700 moles of L-isoleucine 0.0110-0.0700 moles of L-lysine 0.0080-0.0550 moles of L-threonine 0.0135-0.0850 moles of L-valine per liter of solution in water, the pH of which solution being adjusted to fall within the interval 6.0 to 7.0 by addition of a pharmaceutically acceptable organic acid containing only carbon, oxygen and hydrogen.
Claim 15
Dependent Claim
21 words
Method according to claim 15, wherein the solution also contains 0.0125-0.0800 moles of L-arginine and 0.0070-0.0450 moles of L-histidine per liter.
Claim 16
Dependent Claim
16 words
Method according to claim 15, wherein the solution also contains 0.0070-0.0450 moles of L-histidine per liter.
Claim 17
Dependent Claim
46 words
Method according to claim 15, wherein the solution comprises: 0.0375-0.0675 moles of L-phenyl alanine 0.0500-0.0850 moles of L-leucine 0.0425-0.0750 moles of L-methionine 0.0075-0.0125 moles of L-tryptophan 0.0300-0.0550 moles of L-isoleucine 0.0325-0.0575 moles of L-lysine 0.0225-0.0425 moles of L-threonine 0.0400-0.0700 moles of L-valine per liter of solution.
Claim 18
Dependent Claim
21 words
Method according to claim 18, wherein the solution also contains 0.0375-0.0650 moles of L-arginine and 0.0200-0.0375 moles of L-histidine per liter.
Claim 19
Dependent Claim
16 words
Method according to claim 18, wherein the solution also contains 0.0200-0.0375 moles of L-histidine per liter.
Claim 20
Dependent Claim
35 words
Method according to claim 15, wherein the pH of the solution is adjusted to fall within the interval 6.0 to 7.0 by addition of a pharmaceutically acceptable organic acid, containing only carbon, oxygen and hydrogen.
Claim 21
Dependent Claim
26 words
Method according to claim 15, wherein the pH of the solution is adjusted to fall within the interval 6.0 to 7.0 by addition of acetic acid.
Claim 22
Independent Claim
59 words
A method of treating uremic conditions in a patient comprising administering to the patient a tablet comprising essential amino acids in the following internal molar proportions: 0.0130-0.0850 moles of L-phenyl alanine 0.0165-0.1050 moles of L-leucine 0.0145-0.0900 moles of L-methionine 0.0025-0.0200 moles of L-tryptophan 0.0105-0.0700 moles of L-isoleucine 0.0110-0.0700 moles of L-lysine 0.0080-0.0550 moles of L-threonine 0.0135-0.0850 moles of L-valine.
Claim 23
Dependent Claim
16 words
A method as claimed in claim 23, in which the tablet further comprises a protective film.
Claim 24
Dependent Claim
25 words
A method as claimed in claim 24, in which the film comprises a compound selected from the group consisting of polyvinyl acetate and polyethylene glycol.
Claim 25
Dependent Claim
54 words
A method as claimed in claim 23, in which the tablet comprises essential amino acids in the following internal molar proportions: 0.0375-0.0675 moles of L-phenyl alanine 0.0500-0.0850 moles of L-leucine 0.0425-0.0750 moles of L-methionine 0.0075-0.0125 moles of L-tryptophan 0.0300-0.0550 moles of L-isoleucine 0.0325-0.0575 moles of L-lysine 0.0225-0.0425 moles of L-threonine 0.0400-0.0700 moles of L-valine.
Claim 26
Dependent Claim
16 words
A method as claimed in claim 26, in which the tablet further comprises a protective film.
Claim 27
Dependent Claim
26 words
A method as claimed in claim 27, in which the protective film comprises a compound selected from the group consisting of polyvinyl acetate and polyethylene glycol.
Claim 28
Dependent Claim
45 words
A tablet comprising essential amino acids in the following internal molar proportions: 0.0130-0.0850 moles of L-phenyl alanine 0.0165-0.1050 moles of L-leucine 0.0145-0.0900 moles of L-methionine 0.0025-0.0200 moles of L-tryptophan 0.0105-0.0700 moles of L-isoleucine 0.0110-0.0700 moles of L-lysine 0.0800-0.0550 moles of L-threonine 0.0135-0.0850 moles of L-valine.
Claim 29
Dependent Claim
13 words
A tablet as claimed in claim 29 which further comprises a protective film.
Claim 30
Dependent Claim
26 words
A tablet as claimed in claim 30, in which the protective film comprises a compound selected from the group consisting of polyvinyl acetate and polyethylene glycol.
Claim 31
Dependent Claim
45 words
A tablet as claimed in claim 29, comprising amino acids in the following internal molar proportions: 0.0375-0.0675 moles of L-phenyl alanine 0.0500-0.0850 moles of L-leucine 0.0425-0.0750 moles of L-methionine 0.0075-0.0125 moles of L-tryptophan 0.0325-0.0575 moles of L-lysine 0.0225-0.0425 moles of L-threonine 0.0400-0.0700 moles of L-valine.
Claim 32
Dependent Claim
13 words
A tablet as claimed in claim 32, which further comprises a protective film.
Claim 33
Dependent Claim
26 words
A tablet as claimed in claim 32, in which the protective film comprises a compound selected from the group consisting of polyvinyl acetate and polyethylene glycol.
References Cited (Backward Citations)
US3080234A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1976-10-08 | 1977-04-09 | 1977-10-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1980-10-08 | 1981-04-09 | 1981-10-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1984-10-08 | 1985-04-09 | 1985-10-09 | $7700.00 | Window Closed / Lapsed |